278 PRIMARY RESULTS OF A PHASE 1 MULTICENTER OPEN-LABEL STUDY OF ANTOLIMAB, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS AND ELEVATED GASTRIC AND/OR DUODENAL MAST CELLS

Autor:	Amol P. Kamboj, Sabine Hazan, Kathryn A. Peterson, Evan S. Dellon, Bhupinder Singh, Alan T. Chang, Gary W. Falk, Malika Pasha, Adam C. Bledsoe, Kenneth Boren, Ikuo Hirano, Henrik S. Rasmussen, Robert M. Genta
Rok vydání:	2020
Předmět:	Hepatology Open label study biology business.industry Immunology Gastroenterology biology.protein Medicine SIGLEC Antibody business
Zdroj:	Gastroenterology. 158:S-52
ISSN:	0016-5085
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b6ef2838cdea0622a8637a6bc03dd7a2 https://doi.org/10.1016/s0016-5085(20)30815-5 Zobrazit plný text záznamu